145 related articles for article (PubMed ID: 36509740)
21. Treatment of hairy cell leukemia.
Chihara D; Kreitman RJ
Expert Rev Hematol; 2020 Oct; 13(10):1107-1117. PubMed ID: 32893700
[TBL] [Abstract][Full Text] [Related]
22. The applicability of multiparameter flow cytometry for the detection of minimal residual disease using different-from-normal panels to predict relapse in patients with acute myeloid leukemia after allogeneic transplantation.
Wang Z; Guo M; Zhang Y; Xu S; Cheng H; Wu J; Zhang W; Hu X; Yang J; Wang J; Tang G
Int J Lab Hematol; 2019 Oct; 41(5):607-614. PubMed ID: 31162830
[TBL] [Abstract][Full Text] [Related]
23. Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia.
Cloos J; Harris JR; Janssen JJWM; Kelder A; Huang F; Sijm G; Vonk M; Snel AN; Scheick JR; Scholten WJ; Carbaat-Ham J; Veldhuizen D; Hanekamp D; Oussoren-Brockhoff YJM; Kaspers GJL; Schuurhuis GJ; Sasser AK; Ossenkoppele G
J Vis Exp; 2018 Mar; (133):. PubMed ID: 29553571
[TBL] [Abstract][Full Text] [Related]
24. Eradication of minimal residual disease in hairy cell leukemia.
Ravandi F; Jorgensen JL; O'Brien SM; Verstovsek S; Koller CA; Faderl S; Giles FJ; Ferrajoli A; Wierda WG; Odinga S; Huang X; Thomas DA; Freireich EJ; Jones D; Keating MJ; Kantarjian HM
Blood; 2006 Jun; 107(12):4658-62. PubMed ID: 16497968
[TBL] [Abstract][Full Text] [Related]
25. MRD detection in B-cell non-Hodgkin lymphomas using Ig gene rearrangements and chromosomal translocations as targets for real-time quantitative PCR.
Pott C; Brüggemann M; Ritgen M; van der Velden VH; van Dongen JJ; Kneba M
Methods Mol Biol; 2013; 971():175-200. PubMed ID: 23296964
[TBL] [Abstract][Full Text] [Related]
26. The significance of minimal residual disease in hairy cell leukaemia treated with deoxycoformycin: a long-term follow-up study.
Matutes E; Meeus P; McLennan K; Catovsky D
Br J Haematol; 1997 Aug; 98(2):375-83. PubMed ID: 9266936
[TBL] [Abstract][Full Text] [Related]
27. High prognostic value of measurable residual disease detection by flow cytometry in chronic lymphocytic leukemia patients treated with front-line fludarabine, cyclophosphamide, and rituximab, followed by three years of rituximab maintenance.
García-Marco JA; Jiménez JL; Recasens V; Zarzoso MF; González-Barca E; De Marcos NS; Ramírez MJ; Parraga FJP; Yañez L; De La Serna Torroba J; Malo MDG; Ariznavarreta GD; Persona EP; Guinaldo MAR; De Paz Arias R; Llanos EB; Jarque I; Valle MDCF; Tatay AC; De Oteyza JP; Martin EMD; Fernández IP; Martinez RM; Costa MAA; Champ D; Suarez JG; Díaz MG; Ferrer S; Carbonell F; García-Vela JA;
Haematologica; 2019 Nov; 104(11):2249-2257. PubMed ID: 30890600
[TBL] [Abstract][Full Text] [Related]
28. Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.
Mulé MP; Mannis GN; Wood BL; Radich JP; Hwang J; Ramos NR; Andreadis C; Damon L; Logan AC; Martin TG; Hourigan CS
Biol Blood Marrow Transplant; 2016 Nov; 22(11):1974-1982. PubMed ID: 27544285
[TBL] [Abstract][Full Text] [Related]
29. Prognostic value of combined WT1 and multiparameter flow cytometry assessment for measurable residual disease after induction in non-APL acute myeloid leukemia.
Ding Y; Liu Z; Wang H; Xiong S; Zhai Z
Scand J Clin Lab Invest; 2023 Sep; 83(5):340-347. PubMed ID: 37355341
[TBL] [Abstract][Full Text] [Related]
30. Detection of minimal residual disease in B lymphoblastic leukemia by high-throughput sequencing of IGH.
Wu D; Emerson RO; Sherwood A; Loh ML; Angiolillo A; Howie B; Vogt J; Rieder M; Kirsch I; Carlson C; Williamson D; Wood BL; Robins H
Clin Cancer Res; 2014 Sep; 20(17):4540-8. PubMed ID: 24970842
[TBL] [Abstract][Full Text] [Related]
31. Minimal residual disease quantification using consensus primers and high-throughput IGH sequencing predicts post-transplant relapse in chronic lymphocytic leukemia.
Logan AC; Zhang B; Narasimhan B; Carlton V; Zheng J; Moorhead M; Krampf MR; Jones CD; Waqar AN; Faham M; Zehnder JL; Miklos DB
Leukemia; 2013 Aug; 27(8):1659-65. PubMed ID: 23419792
[TBL] [Abstract][Full Text] [Related]
32. Randomized Phase II Study of First-Line Cladribine With Concurrent or Delayed Rituximab in Patients With Hairy Cell Leukemia.
Chihara D; Arons E; Stetler-Stevenson M; Yuan CM; Wang HW; Zhou H; Raffeld M; Xi L; Steinberg SM; Feurtado J; James L; Wilson W; Braylan RC; Calvo KR; Maric I; Dulau-Florea A; Kreitman RJ
J Clin Oncol; 2020 May; 38(14):1527-1538. PubMed ID: 32109194
[TBL] [Abstract][Full Text] [Related]
33. Importance of minimal residual disease in hairy cell leukemia: monoclonal antibodies as a therapeutic strategy.
Thomas DA; Ravandi F; Keating M; Kantarjian HM
Leuk Lymphoma; 2009 Oct; 50 Suppl 1(0 1):27-31. PubMed ID: 19814695
[TBL] [Abstract][Full Text] [Related]
34. Comparative analysis of minimal residual disease detection using four-color flow cytometry, consensus IgH-PCR, and quantitative IgH PCR in CLL after allogeneic and autologous stem cell transplantation.
Böttcher S; Ritgen M; Pott C; Brüggemann M; Raff T; Stilgenbauer S; Döhner H; Dreger P; Kneba M
Leukemia; 2004 Oct; 18(10):1637-45. PubMed ID: 15343348
[TBL] [Abstract][Full Text] [Related]
35. Vemurafenib plus Rituximab in Refractory or Relapsed Hairy-Cell Leukemia.
Tiacci E; De Carolis L; Simonetti E; Capponi M; Ambrosetti A; Lucia E; Antolino A; Pulsoni A; Ferrari S; Zinzani PL; Ascani S; Perriello VM; Rigacci L; Gaidano G; Della Seta R; Frattarelli N; Falcucci P; Foà R; Visani G; Zaja F; Falini B
N Engl J Med; 2021 May; 384(19):1810-1823. PubMed ID: 33979489
[TBL] [Abstract][Full Text] [Related]
36. Utility of Measurable Residual Disease (MRD) Assessment in Mantle Cell Lymphoma.
Wu S; Blombery P; Westerman D; Tam CS
Curr Treat Options Oncol; 2023 Aug; 24(8):929-947. PubMed ID: 37249800
[TBL] [Abstract][Full Text] [Related]
37. Implications of minimal residual disease in hairy cell leukemia after cladribine using immunohistochemistry and immunophenotyping.
Tallman MS
Leuk Lymphoma; 2011 Jun; 52 Suppl 2():65-8. PubMed ID: 21463116
[TBL] [Abstract][Full Text] [Related]
38. Potential predictive patterns of minimal residual disease detected by immunohistochemistry on bone marrow biopsy specimens during a long-term follow-up in patients treated with cladribine for hairy cell leukemia.
Mhawech-Fauceglia P; Oberholzer M; Aschenafi S; Baur A; Kurrer M; Von Rohr A; Hsu-Schmitz SF; Wagner B; Delacretaz F; Hurwitz N;
Arch Pathol Lab Med; 2006 Mar; 130(3):374-7. PubMed ID: 16519567
[TBL] [Abstract][Full Text] [Related]
39. Minimal residual disease (MRD) monitoring using rearrangement of T-cell receptor and immunoglobulin H gene in the treatment of adult acute lymphoblastic leukemia patients.
Toubai T; Tanaka J; Ota S; Fukuhara T; Hashino S; Kondo T; Kasai M; Kakinoki Y; Masauzi N; Morioka M; Kawamura T; Iwasaki H; Asaka M; Imamura M
Am J Hematol; 2005 Nov; 80(3):181-7. PubMed ID: 16247752
[TBL] [Abstract][Full Text] [Related]
40. [Assessment of minimal residual disease in adult patients with B-lineage acute lymphoblastic leukemia using rearranged immunoglobulin loci detection].
Yao L; Chen ZX; Cen JN; Liu H; He J; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2010 Jul; 31(7):433-7. PubMed ID: 21122394
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
